Genocea Biosciences, Inc., is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company has one product candidate in Phase III clinical development, GEN-003, an immunotherapy for the treatment of genital herpes. It also has a pre-clinical immuno-oncology program focused on personalized cancer vaccines (GEN-009). The GEN-009 program leverages ATLAS to identify patient neoantigens, or newly formed antigens unique to each patient, that are associated with that individual's tumor.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Symbol: NASDAQ:GNCA
- CUSIP: N/A
- Web: www.genocea.com
- Market Cap: $168.16 million
- Outstanding Shares: 28,502,000
- 50 Day Moving Avg: $6.30
- 200 Day Moving Avg: $5.11
- 52 Week Range: $3.28 - $7.29
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -3.14
- P/E Growth: 0.00
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $1.16 per share
- Price / Book: 5.09
- EBIDTA: ($51,980,000.00)
- Return on Equity: -57.92%
- Return on Assets: -44.92%
- Debt-to-Equity Ratio: 0.25%
- Current Ratio: 10.79%
- Quick Ratio: 10.79%
- Average Volume: 231,389 shs.
- Beta: 2.33
- Short Ratio: 14.96
Frequently Asked Questions for Genocea Biosciences (NASDAQ:GNCA)
What is Genocea Biosciences' stock symbol?
Genocea Biosciences trades on the NASDAQ under the ticker symbol "GNCA."
How were Genocea Biosciences' earnings last quarter?
Genocea Biosciences Inc (NASDAQ:GNCA) announced its quarterly earnings data on Thursday, May, 4th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.54) by $0.06. View Genocea Biosciences' Earnings History.
Where is Genocea Biosciences' stock going? Where will Genocea Biosciences' stock price be in 2017?
4 brokerages have issued 1 year target prices for Genocea Biosciences' stock. Their forecasts range from $12.00 to $40.00. On average, they anticipate Genocea Biosciences' share price to reach $21.00 in the next year. View Analyst Ratings for Genocea Biosciences.
What are analysts saying about Genocea Biosciences stock?
Here are some recent quotes from research analysts about Genocea Biosciences stock:
- 1. According to Zacks Investment Research, "Genocea Biosciences, Inc. is involved in developing vaccines. The company's proprietary discovery platform consists of AnTigen Lead Acquisition System which designs vaccines that stimulate T cell immunity. Its product portfolio which are in different clinical trials consist of GEN-003, HSV-2 infections, GEN-004 and HSV-2 prophylaxis and malaria. Genocea Biosciences, Inc. is headquartered in Cambridge, Massachusetts. " (5/16/2017)
- 2. Needham & Company LLC analysts commented, "Genocea announced positive results from its Phase 2b trial of GEN-003 in Herpes Simplex Type 2 (HSV2) in early Jan 2017. Given financial constraints, however, mgmt now plans to seek a collaborator prior to initiation of Phase 3 development. We believe this creates meaningful uncertainty for GEN-003 development timelines as well as the stock. Mgmt previously announced a shift in strategic focus from infectious disease to immuno-oncology. However, initial candidate from latter program is not expected to reach clinical development until YE17. We are downgrading to HOLD based on uncertainty around GEN-003 and lack of near-term milestones w/ immuno-oncology program. ATLAS platform holds substantial value and we believe stock remains attractive for long-term investors w/ horizon beyond 2017." (2/17/2017)
Are investors shorting Genocea Biosciences?
Genocea Biosciences saw a drop in short interest during the month of April. As of April 28th, there was short interest totalling 2,816,384 shares, a drop of 1.7% from the April 13th total of 2,864,960 shares. Based on an average daily trading volume, of 314,606 shares, the days-to-cover ratio is presently 9.0 days.
Who are some of Genocea Biosciences' key competitors?
Some companies that are related to Genocea Biosciences include ChemoCentryx (CCXI), Corbus Pharmaceuticals Holdings (CRBP), GlycoMimetics (GLYC), Ocular Therapeutix (OCUL), Nantkwest (NK), Minerva Neurosciences (NERV), Edge Therapeutics (EDGE), Sinovac Biotech (SVA), Concert Pharmaceuticals (CNCE), Ignyta (RXDX), Novavax (NVAX), Dynavax Technologies (DVAX), XBiotech (XBIT), Veracyte (VCYT), Nabriva Therapeutics AG - (NBRV), SIGA Technologies (SIGA), Kamada Ltd (KMDA) and Compugen (CGEN).
Who owns Genocea Biosciences stock?
Genocea Biosciences' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (15.03%), Polaris Venture Management Co. V L.L.C. (6.91%), Northpointe Capital LLC (4.28%), Vanguard Group Inc. (2.64%), Sphera Funds Management LTD. (2.27%) and AXA (2.14%). Company insiders that own Genocea Biosciences stock include Eric S Hoffman, Jessica Baker Flechtner, Jonathan Poole, Polaris Venture Management Co and William D Clark. View Institutional Ownership Trends for Genocea Biosciences.
Who sold Genocea Biosciences stock? Who is selling Genocea Biosciences stock?
Who bought Genocea Biosciences stock? Who is buying Genocea Biosciences stock?
Genocea Biosciences' stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., JPMorgan Chase & Co., Segantii Capital Management Ltd, Keybank National Association OH, FMR LLC, Geode Capital Management LLC, Ameriprise Financial Inc. and AXA. Company insiders that have bought Genocea Biosciences stock in the last two years include Eric S Hoffman, Jonathan Poole and William D Clark. View Insider Buying and Selling for Genocea Biosciences.
How do I buy Genocea Biosciences stock?
Shares of Genocea Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Genocea Biosciences stock cost?
One share of Genocea Biosciences stock can currently be purchased for approximately $5.90.
Earnings History for Genocea Biosciences (NASDAQ:GNCA)Earnings History by Quarter for Genocea Biosciences (NASDAQ:GNCA)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Genocea Biosciences (NASDAQ:GNCA)
Current Year EPS Consensus Estimate: $-1.89 EPS
Next Year EPS Consensus Estimate: $-1.88 EPS
Dividend History for Genocea Biosciences (NASDAQ:GNCA)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Genocea Biosciences (NASDAQ:GNCA)
Insider Ownership Percentage: 19.10%Insider Trades by Quarter for Genocea Biosciences (NASDAQ:GNCA)
Institutional Ownership Percentage: 54.62%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|11/8/2016||Eric S. Hoffman||Insider||Buy||7,000||$3.49||$24,430.00|| |
|11/7/2016||Jonathan Poole||CFO||Buy||7,000||$3.34||$23,380.00|| |
|11/7/2016||William D. Clark||Insider||Buy||2,800||$3.49||$9,772.00|| |
|5/9/2016||Jonathan Poole||CFO||Buy||4,000||$3.88||$15,520.00|| |
|12/16/2015||William D Clark||CEO||Buy||3,800||$6.45||$24,510.00|| |
|9/1/2015||Jessica Baker Flechtner||VP||Sell||2,229||$11.35||$25,299.15|| |
|6/19/2015||Polaris Venture Management Co.||Major Shareholder||Sell||30,004||$13.04||$391,252.16|| |
|6/17/2015||Polaris Venture Management Co.||Major Shareholder||Sell||10,618||$13.01||$138,140.18|| |
|6/16/2015||Polaris Venture Management Co.||Major Shareholder||Sell||46,000||$13.24||$609,040.00|| |
|6/1/2015||Jessica Baker Flechtner||VP||Sell||2,229||$10.52||$23,449.08|| |
|5/1/2015||Jessica Baker Flechtner||VP||Sell||2,229||$10.21||$22,758.09|| |
|4/1/2015||Jessica Baker Flechtner||VP||Sell||2,283||$11.77||$26,870.91|| |
|3/17/2015||Stephen J Hoffman||Director||Buy||700,000||$8.25||$5,775,000.00|| |
|2/2/2015||Jessica Baker Flechtner||VP||Sell||4,699||$8.50||$39,941.50|| |
|9/12/2014||Jessica Baker Flechtner||VP||Sell||6,435||$12.00||$77,220.00|| |
|9/11/2014||Paul Giannasca||VP||Sell||4,071||$11.84||$48,200.64|| |
|9/10/2014||Paul Giannasca||VP||Sell||834||$12.35||$10,299.90|| |
|9/9/2014||Paul Giannasca||VP||Sell||2,455||$12.43||$30,515.65|| |
|9/8/2014||Paul Giannasca||VP||Sell||2,970||$12.80||$38,016.00|| |
|8/29/2014||Paul Giannasca||VP||Sell||6,760||$12.50||$84,500.00|| |
|8/14/2014||Polaris Venture Management Co.||Major Shareholder||Sell||9,660||$13.01||$125,676.60|| |
|8/12/2014||Polaris Venture Management Co.||Major Shareholder||Sell||63,794||$13.28||$847,184.32|| |
|2/10/2014||Plc Glaxosmithkline||Insider||Buy||143,773||$12.00||$1,725,276.00|| |
|2/10/2014||Polaris Venture Management Co.||Major Shareholder||Buy||232,820||$12.00||$2,793,840.00|| |
|2/10/2014||Stephen J Hoffman||Director||Buy||250,931||$12.00||$3,011,172.00|| |
Headline Trends for Genocea Biosciences (NASDAQ:GNCA)
Latest Headlines for Genocea Biosciences (NASDAQ:GNCA)
|Genocea Biosciences Inc (GNCA) Given Consensus Recommendation of "Buy" by Brokerages|
www.americanbankingnews.com - May 22 at 7:56 AM
|Genocea Biosciences Inc (GNCA) Lifted to Buy at Zacks Investment Research|
www.americanbankingnews.com - May 16 at 10:40 PM
|Genocea Biosciences Inc (GNCA) Short Interest Update|
www.americanbankingnews.com - May 16 at 7:20 AM
|Genocea Biosciences Inc (GNCA) Issues Earnings Results|
www.americanbankingnews.com - May 8 at 4:40 PM
|Genocea Reports First Quarter 2017 Financial Results and Positive Clinical Developments on Lead Candidate GEN-003 in Genital Herpes|
finance.yahoo.com - May 4 at 12:07 PM
|Investor Network: Genocea Biosciences, Inc. to Host Earnings Call|
finance.yahoo.com - May 4 at 12:07 PM
|Genocea Biosciences reports 1Q loss|
marketbeat.com - May 4 at 9:29 AM
|Zacks: Brokerages Expect Genocea Biosciences Inc (GNCA) Will Post Earnings of -$0.54 Per Share|
www.americanbankingnews.com - May 2 at 12:06 AM
|Genocea Biosciences (GNCA) Earning Somewhat Critical Media Coverage, Analysis Shows|
www.americanbankingnews.com - April 30 at 8:02 AM
|Genocea to Host First Quarter 2017 Financial Results Conference Call & Webcast on May 4, 2017 at 9 a.m. ET|
finance.yahoo.com - April 27 at 8:05 AM
|Somewhat Positive Press Coverage Extremely Likely to Impact Genocea Biosciences (GNCA) Stock Price|
www.americanbankingnews.com - April 26 at 8:44 AM
|Genocea Biosciences Inc (GNCA) Given Average Rating of "Buy" by Brokerages|
www.americanbankingnews.com - April 25 at 11:05 AM
|Genocea Biosciences (GNCA) Receives Media Impact Score of -0.22|
www.americanbankingnews.com - April 20 at 8:53 AM
|Genocea Biosciences (GNCA) Receiving Very Favorable Media Coverage, AlphaOne Reports|
www.americanbankingnews.com - April 15 at 8:58 AM
|Genocea Awarded World Vaccine Congress 2017 Industry Excellence Award for Best Therapeutic Vaccine for GEN-003 for Genital Herpes|
finance.yahoo.com - April 11 at 12:15 PM
| Brokerages Anticipate Genocea Biosciences Inc (GNCA) Will Post Earnings of -$0.54 Per Share|
www.americanbankingnews.com - April 10 at 8:30 PM
|Genocea Biosciences (GNCA) Presents At 16th Annual Needham Healthcare Conference - Slideshow|
seekingalpha.com - April 7 at 10:05 AM
|Genocea Biosciences Inc (GNCA) Given Consensus Rating of "Buy" by Brokerages|
www.americanbankingnews.com - March 30 at 12:58 PM
|Genocea to Present at the 16th Annual Needham Healthcare Conference|
finance.yahoo.com - March 29 at 11:07 AM
|Genocea Biosciences (GNCA) Jumps: Stock Moves 12% Higher - Nasdaq|
www.nasdaq.com - March 9 at 5:55 PM
|Genocea Biosciences (GNCA) Presents At Cowen and Company 37th Annual Health Care Conference|
seekingalpha.com - March 8 at 6:17 PM
|Genocea Biosciences (GNCA) Appoints Howard Mayer M.D. to ... - StreetInsider.com|
www.streetinsider.com - March 7 at 11:22 AM
|GENOCEA BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh|
biz.yahoo.com - March 6 at 5:08 PM
|Howard Mayer, M.D., of Shire, Joins Genocea Biosciences’ Board of Directors|
finance.yahoo.com - March 6 at 9:27 AM
|Genocea to Present at the Cowen and Company 37th Annual Health Care Conference|
finance.yahoo.com - March 1 at 12:15 PM
|GENOCEA BIOSCIENCES, INC. Financials|
finance.yahoo.com - February 23 at 5:29 PM
|GENOCEA BIOSCIENCES, INC. Files SEC form 10-K, Annual Report|
biz.yahoo.com - February 18 at 12:23 PM
|Genocea Biosciences downgraded by Needham|
finance.yahoo.com - February 17 at 4:04 PM
|Q4 2016 Genocea Biosciences Inc Earnings Release - Time Not Supplied|
us.rd.yahoo.com - February 16 at 5:24 PM
|Genocea Reports Fourth Quarter and Year-End 2016 Financial Results|
us.rd.yahoo.com - February 16 at 5:24 PM
|GENOCEA BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and|
us.rd.yahoo.com - February 16 at 5:24 PM
|Genocea to Host Fourth Quarter and Year End 2016 Financial Results Conference Call & Webcast on February 16, 2017|
finance.yahoo.com - February 9 at 6:16 PM
|Should You Sell Genocea Biosciences (GNCA) Before Earnings? - Nasdaq|
www.nasdaq.com - February 8 at 11:06 PM
|Should You Sell Genocea Biosciences (GNCA) Before Earnings?|
finance.yahoo.com - February 7 at 6:45 PM
|Genocea Reports Positive 6-Month Results From GEN-003 Phase 2b Trial|
www.nasdaq.com - January 5 at 6:25 PM
|Genocea Biosciences (GNCA) Announces Positive Interim Analysis of GEN-003 Phase 2b Clinical Trial|
www.streetinsider.com - January 5 at 6:25 PM
Genocea Biosciences (GNCA) Chart for Saturday, May, 27, 2017